L - Carnitina 2000 líquida (400ml)
US$ 22.79
acetaminophen toxicity glutathione depletion Illustration of the effects of on glutathione, Sex differences in glutathione metabolism
Description
The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
Systemic treatment of pancreatic cancer revisited
FOXO4-DRI 10 mg (Proxofim) Cellular Senolytic Peptide
Microbiome and gut dysbiosis
